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2Abstract
Aims: Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognised, progressive
and fatal cardiomyopathy, the natural history of which remains unclear. We sought to
establish and validate a new prognostic staging system applicable to patients with both wild-
type (ATTRwt) and hereditary variant (ATTRv) ATTR amyloid cardiomyopathy.
Methods and Results: Eight hundred and sixty-nine patients with cardiac ATTR
amyloidosis (553 with ATTRwt and 316 with ATTRv) attending the UK National
Amyloidosis Centre, were stratified into 3 disease stages at baseline on the basis of cut points
in two universally measured biomarkers, NT-proBNP and estimated GFR (eGFR). Stage I
was defined as NT-proBNP ≤3000 ng/L and eGFR ≥45 ml/min, Stage III was NT-proBNP 
>3000 ng/L and eGFR <45 ml/min; the remainder were Stage II. The staging system was
validated in a cohort of 318 patients with cardiac ATTR amyloidosis from France. Median
survival among 393 (45%) Stage I patients was 69.2 months, 334 (38%) Stage II patients was
46.7 months, and 142 (16%) Stage III patients was 24.1 months (p<0.0001). After adjusting
for age, compared to Stage I the hazard ratio (HR) for death for Stage II was 2.05 (CI: 1.54-
2.72, p<0.001) and for Stage III was 3.80 (CI: 2.73-5.28, p<0.001). HRs and statistical
significance were little altered by TTR genotype, and were maintained in the validation
cohort.
Conclusions: This simple, universally applicable staging system stratifies patients with both
ATTRwt and ATTRv amyloid cardiomyopathy into prognostic categories. It will be of value
in the design of forthcoming clinical trials of novel amyloid-specific therapies.
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3Introduction
Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognised cause of heart failure
among older individuals.1 It is an inexorably progressive and eventually fatal restrictive
cardiomyopathy. The causative amyloid deposits in the heart may be composed of either
wild-type (non-mutated) transthyretin or variant transthyretin (TTR), the latter associated
with numerous mutations in the TTR gene.
Until recently, diagnosis of cardiac ATTR amyloidosis required demonstration of
amyloid deposits within an endomyocardial biopsy.2 However, advances in diagnostic
imaging techniques, including cardiac magnetic resonance imaging (CMR)3,4 and bone
scintigraphy with technetium-labelled DPD,5,6 HMDP,7 and PYP8 have enabled non-invasive,
non-histological diagnosis of cardiac ATTR amyloidosis, resulting in a greater than 30 fold
increase in diagnosis of this condition in our centre during the past decade. The non-biopsy
algorithm for diagnosis of cardiac ATTR amyloidosis was recently validated in an
international multi-centre study.9
Wild-type ATTR amyloidosis is a condition of older, usually male, individuals.10 The
commonest genetic variants associated with hereditary ATTR amyloid cardiomyopathy are
TTR V122I, present in 3-4% of African Americans,11 and TTR T60A, present in many
populations with a frequency of up to 1% in one North Western Irish study.12 Numerous
other rare TTR variants are also associated with ATTR amyloid cardiomyopathy.13 The
diagnosis is made at different stages of the natural history of the disease, reflecting awareness
within families and physicians, imaging and other resources, and heterogeneous
presentations, but the course of both wild-type10 and variant ATTR cardiac amyloidosis is
ultimately that of gradually progressive cardiac failure and death within 10 years. Current
management is symptomatic, centred on rhythm control, diuretics and careful regulation of
fluid balance. Although there are no specific therapies as yet, a number of targeted anti–
4amyloid agents, designed either to inhibit ATTR amyloid deposition or to clear away existing
cardiac amyloid deposits, are now in phase 2 and 3 clinical trials and are showing great
promise.14-17
Currently, there is no substantiated staging system for cardiac ATTR amyloidosis.
Grogan and colleagues recently proposed a staging system using N-terminal pro-B-type
natriuretic peptide (NT-proBNP) and troponin T (TnT) for wild-type ATTR amyloidosis but
this has not been validated and has not been applied to variant ATTR amyloidosis.18 Further,
this system is confounded by current worldwide use of five generations of troponin assays
made by various manufacturers, with different centres favouring different assays. These
include newer high sensitivity troponin T (hs-TnT) assays, which not only differ in sensitivity
but also give different numerical results to older assays, and troponin I assays.19 We recently
identified NT-proBNP and estimated GFR (eGFR), along with age, to be independent
prognostic factors in cardiac ATTR amyloidosis20 and sought to investigate and validate a
staging system for cardiac ATTR amyloidosis which is applicable to both wild-type and
variant ATTR amyloid cardiomyopathy based on these two simple, universally employed,
biomarkers.
Methods
Patients
A retrospective analysis of 869 patients diagnosed with cardiac ATTR amyloidosis on the
basis of the presence of heart failure in conjunction with either endomyocardial biopsy
histology confirming ATTR amyloid or previously established non-biopsy diagnostic
criteria,9 who were routinely followed at the UK National Amyloidosis Centre, was
performed to establish the staging system (test cohort). All patients had undergone
sequencing of the TTR gene on the basis of which 553 were diagnosed with wild-type ATTR
5cardiac amyloidosis (sub-group 1), 201 were diagnosed with V122I-associated cardiac ATTR
amyloidosis (sub-group 2), and 115 were diagnosed with cardiac ATTR amyloidosis in
association with other pathogenic TTR variants (sub-group 3); T60A (p.T80A) (n=86), S77Y
(p.S97Y) (n=12), D38V (p.D58V), D38Y (p.D58Y), A97S (p.A117S), E42D (p.E62D),
E54K (p.E74K), E54L (p.E74L), E89K (p.E109K), E89Q (p.E109Q), F44L (p.F64L), G53A
(p.G73A), I107F (p.I127F), I68L (p.I88L), I73V (p.I93V), I84S (p.I104S), I84T (p.I104T),
L12P (p.L32P), and Y69F (p.Y89F) in one patient each. Patients with V30M-associated
ATTR amyloidosis, which often has a predominantly neuropathic phenotype without
cardiomyopathy, were excluded from all analyses.
All patients were managed in accordance with the Declaration of Helsinki and
provided informed consent for anonymous publication of scientific data.
Biomarkers
NT-proBNP was measured with an electrochemiluminescence sandwich immunoassay on the
Elecsys system 2010 (Roche Diagnostics). GFR was estimated (eGFR) according to the
standard MDRD formula (including the correction for race). High-sensitivity troponin T
assay was performed with a second-generation assay after 16th December 2015, and prior to
that, with a first generation troponin T assay.
Statistical Methods
The mortality endpoint was defined as time to death from baseline for all deceased
patients and time to Censor date, 18th May 2017, from baseline among the remainder. Date
of baseline was the same as date of diagnosis in >95% of patients and was within one month
of diagnosis in nearly all remaining patients, such that median time from diagnosis to
baseline was 0 months. Accuracy of occurrence and date of death among deceased patients,
6and ongoing survival among those who were censored, was ensured on the basis of UK death
certificate data from the UK Office of National Statistics.
In order to define the staging system, optimal cut points for relevant variables were
chosen on the basis of a receiver operating characteristic curve and then by the Youden
method. For NT-proBNP the optimal cut was 3806 ng/L which gave a sensitivity of 56% and
specificity of 68%. A cut point of 3000 ng/L gave a sensitivity of 67% and specificity of
57%. The optimal cut point for eGFR was 49 ml/min/1.73m2 (sensitivity 78%, specificity
38%) and a cut point of 45 ml/min/1.73m2 (eGFR <45 ml/min/1.73m2 defines chronic kidney
disease stage 3b) gave a sensitivity of 84% and specificity of 32%. Median NT-proBNP in
the test cohort was ~3000 ng/L and this cut point along with NT-proBNP of 4000 ng/L were
both good discriminators of survival by log rank tests. Different cut points for eGFR alone
(according to established CKD stages) were then tested for their discriminatory value for
survival, and both 45 ml/min and 30 ml/min were discriminatory. Given the Youden method
results, models using both NT-proBNP of 3000 ng/L and 4000 ng/L and eGFR
45 ml/min/1.73m2 were then tested for their discriminatory ability and proportional
representation. The eGFR cut point of 45 ml/min/1.73m2 when combined with the NT-
proBNP cut point of 3000 ng/L enhanced the discriminatory ability of all models of BNP
alone (including an NT-proBNP tertile model), eGFR alone (including an eGFR tertile
model) whilst dividing an acceptable proportion of patients into each of three stages. Kaplan-
Meier plots were used to view survival from baseline in different groups. Cox proportional
hazards regression analysis was used to compare the hazard ratios (HR) for the three stages in
the whole cohort and separately for each of the three amyloid sub-groups, with age as a
covariate. Results of the age-adjusted models are summarised using estimated hazard ratios
with their 95% confidence interval (CI). Harrell’s c-statistic was calculated to measure the
discriminatory ability of each model.
7The staging system was validated using a cohort of 318 patients, comprising all
patients diagnosed with cardiac ATTR amyloidosis and followed at Mondor Amyloidosis
Network, Henri Mondor Teaching Hospital, Créteil, France.
Two-sided tests were used for all analyses, and P<0.05 was considered significant.
The data were analysed using Stata (StataCorp. 2015. Stata Statistical Software: Release 14.
College Station, TX: StataCorp LP). The HRs from the previously published staging system
using troponin T were determined by Cox proportional hazards regression analysis and
compared to those of the currently proposed staging system. The unavoidable
methodological limitations of this comparison, due to the replacement of an earlier generation
troponin T assay by a high sensitivity troponin T assay on 16th December 2015, are
acknowledged.
Results
Baseline characteristics of all patients in the test cohort are shown in Table 1. Seven
hundred and thirty-five patients (85%) were male, and median age at baseline was 77 years.
As expected, the majority of patients with wild-type ATTR and non-V122I-associated variant
ATTR amyloidosis were Caucasian and nearly all of those with V122I-associated ATTR
amyloidosis were of African ancestry.
Median follow up in the whole test cohort using a reversed survival model was 32.2
months (range 0.1-116 months) and median survival from baseline by Kaplan Meier analysis
was 57 months (95% CI: 49.1 – 60.4 months). Two-hundred and eight-one patients died
during follow up. Univariable and multivariable analyses of factors associated with death are
shown in Supplementary Tables 1 and 2 respectively.
By univariable analyses, NT-proBNP >3000 ng/L and eGFR <45 ml/min/1.73m2 were
each found to be significantly associated with death (log rank test, p<0.0001; Figure 1). A
8staging system was then created using biomarker cutoffs of 3000 ng/L for NT-proBNP and
45 ml/min/1.73m2 for eGFR. Stage I was defined as NT-proBNP below or equal to the cutoff
and eGFR above or equal to the cutoff, Stage III was defined as NT-proBNP above the cutoff
and eGFR below the cutoff and the remainder were classified as Stage II. Three hundred and
ninety-three (45%) patients were classified as Stage I, 334 (38%) patients were Stage II and
142 (16%) patients were Stage III. Survival probabilities by Kaplan-Meier analysis stratified
by Stage for the whole test cohort are shown in Figure 2. Stage I patients had a median
survival of 69.2 months (95% CI: lower limit 62.9 months, upper limit indeterminable),
Stage II patients had a median survival of 46.7 months (95% CI: 40.2–57.0 months) and
Stage III patients had a median survival of 24.1 months (95% CI: 21.2-29.6 months
(p<0.0001 for Stage I vs II and p< 0.0001 for Stage II vs III). After adjusting for age,
compared to Stage I, the hazard ratio for death was 2.05 (95% CI: 1.54-2.72, p<0.001) for
Stage II, and 3.80 (95% CI: 2.73-5.28, p<0.001) for Stage III patients. The hazard ratio for
death in patients with Stage III cardiac ATTR amyloidosis compared to Stage II cardiac
ATTR amyloidosis was 1.86 (95% CI: 1.38-2.48, p<0.0001). Harrell’s c statistic was 0.69
(Table 2).
Among the subset of 553 patients with wild-type ATTR cardiac amyloidosis (sub-
group 1), 234 (42%) were classified as stage I, 219 (40%) were stage II, and 100 (18%)
patients were stage III. Survival in wild-type ATTR amyloidosis by Kaplan-Meier analysis,
stratified by Stage is shown in Figure 3. Stage I patients had a median survival that was
indeterminable, Stage II patients had a median survival of 49.2 months (95% CI: lower limit
41.3 months, upper limit indeterminable) and Stage III patients had a median survival of 32.7
months (95% CI: 23.4-37.0 months) (p<0.0001 for Stage I vs II and p=0.0003 for Stage II vs
III). After adjusting for age in wild-type ATTR amyloidosis, compared to Stage I, the hazard
9ratio for death was 2.26 (95% CI: 1.51-3.36, p<0.001) for Stage II, and 4.37 (95% CI: 2.80-
6.83, p<0.001) for Stage III (Table 2).
Among the subset of 201 patients with V122I-associated ATTR amyloidosis (sub-
group 2), 89 (44%) were classified as stage I, 79 (40%) were Stage II, and 33 (16%) patients
were Stage III. Survival in V122I-associated ATTR amyloidosis by Kaplan-Meier analysis,
stratified by Stage is shown in Figure 4. Stage I patients had a median survival of 54.4
months (95% CI: lower limit 31.1 months, upper limit indeterminable), Stage II patients had
a median survival of 28.8 months (95% CI: 23.6–45.1 months) and Stage III patients had a
median survival of 17.7 months (95% CI: 11.5–22.3 months) (p=0.006 for Stage I vs II and
p=0.013 for Stage II vs III). After adjusting for age in V122I-associated ATTR amyloidosis,
compared to Stage I, the hazard ratio for death was 1.91 (95% CI: 1.17-3.12, p=0.009) for
Stage II, and 3.48 (95% CI: 1.94-6.27, p<0.001) for Stage III patients (Table 2).
Among the subset of 115 patients with cardiac ATTR amyloidosis associated with
variants other than V122I (sub-group 3), 70 (61%) were classified as Stage I, 36 (31%) were
Stage II, and 9 (8%) patients were Stage III. Survival in non-V122I-associated variant ATTR
amyloidosis by Kaplan-Meier analysis, stratified by Stage is shown in Figure 5. Stage I
patients had a median survival of 76.7 months (95% CI: lower limit 69.0 months, upper limit
indeterminable), Stage II patients had a median survival of 54.0 months (95% CI: 28.6–74.6)
and Stage III patients had a median survival of 24.1 months (95% CI: lower limit 6.3 months,
upper limit indeterminable) (p<0.02 for Stage I vs II and p<0.03 for Stage II vs III). After
adjusting for age in non-V122I-associated variant ATTR amyloidosis, compared to Stage I,
the hazard ratio for death was 2.28 (95% CI: 1.04-4.98, p=0.039) for Stage II, and 4.05 (95%
CI: 1.54-10.64, p=0.005) for Stage III patients (Table 2).
The staging system was applied to the validation cohort of 318 patients with cardiac
ATTR amyloidosis; this cohort consisted of 186 patients with wild-type ATTR amyloidosis,
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68 patients with V122I-associated ATTR amyloidosis and 64 patients with 21 other known
pathogenic TTR variants resulting in cardiac ATTR amyloidosis, including 16 variants that
were not included in the test cohort. The baseline characteristics of the validation cohort are
shown in Table 1. Despite the ‘unselected’ nature of the validation cohort, formal calibration
with the test cohort indicated remarkable consistency across all three disease stages and a
calibration coefficient of 0.999. One hundred and fifty (47%) patients were classified as
Stage I, 118 (37%) patients were Stage II and 50 (16%) patients were Stage III. Survival by
Kaplan-Meier analysis stratified by stage is shown in Figure 6 and the results from Cox
proportional hazards regression analysis, adjusting for age, are shown in Table 2. Stage I
patients had a median survival of 69.2 months, Stage II patients had a median survival of 35.0
months and Stage III patients had a median survival of 20.5 months (p<0.0001 for Stage I vs
II and P=0.01 for Stage II vs III). After adjusting for age, compared to Stage I, the hazard
ratio for death was 3.36 (95% CI: 1.79-6.29, p<0.001) for Stage II, and 6.92 (95%CI: 3.45-
13.87, p<0.001) for Stage III patients. The hazard ratio for patients with Stage III cardiac
ATTR amyloidosis compared to Stage II was 2.06 (95% CI: 1.12-3.79, p=0.020). Harrell’s c
statistic was 0.71 (Table 2).
Comparison of hazard ratios for death between this and the previously reported
staging system which used Troponin T and NT-proBNP is shown in Table 2.
Discussion
We present a staging system that is applicable to both wild-type ATTR and variant ATTR
cardiac amyloidosis, using two simple and universally measured serum biomarkers, NT-
proBNP and eGFR. Patients are diagnosed with cardiac ATTR amyloidosis at different
stages in its natural history and this staging system, which is highly informative on prognosis
and will be relevant for stratifying the enrolment of patients into forthcoming clinical trials of
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novel therapies, represents an important advance, particularly given its simplicity and wide
applicability. The staging system discriminates between the ~20% patients with cardiac
ATTR amyloidosis who have a median survival of approximately 2 years, the 40% who have
a median survival of about 4 years, and the ~40% who have a median survival of around 6
years. Whilst our data validate the previously proposed staging system in wild-type ATTR
amyloidosis, using Troponin T and NT-proBNP measurement, this cardiac biomarker based
system in our own large dataset was less discriminatory and less consistent with respect to
hazard ratios of death across different genotypes than our NT-proBNP and eGFR system, the
performance of which was remarkably similar across all pathogenic TTR genotypes and
between the test and validation cohorts (Table 2). This, coupled with the widespread
availability and consistent inter-assay performance of both the eGFR and NT-proBNP
biomarkers used in our staging system, leads us to recommend widespread adoption of this
staging system in patients with cardiac ATTR amyloidosis.
Interestingly, a smaller proportion of patients with non-V122I-associated hereditary
cardiac ATTR amyloidosis had Stage III disease at the time of diagnosis compared with other
types of cardiac ATTR amyloidosis studied here. This is perhaps not surprising since
patients with most other pathogenic TTR variants usually have additional autonomic and
peripheral nerve amyloidosis, i.e., familial amyloid polyneuropathy,21 along with a family
history of a similar disease phenotype in a first degree relative such that they may
conceivably seek medical attention with earlier cardiac involvement than patients with wild-
type ATTR amyloidosis or V122I-associated cardiac ATTR amyloidosis who are usually
diagnosed after developing overt cardiac symptoms.22 Nonetheless, with the notable
exception of V30M-associated ATTR amyloidosis which frequently presents with isolated
neuropathic symptoms in the absence of cardiomyopathy (hence exclusion of such patients
from this study), by the time patients with non-V122I hereditary ATTR amyloidosis are
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diagnosed, there is invariably evidence of the characteristic amyloid cardiomyopathy and
heart failure on investigation using biomarkers, imaging and histology.
It is also noteworthy that despite there being a similar proportion of patients with
V122I-associated cardiac ATTR amyloidosis and wild-type ATTR cardiac amyloidosis
classified with Stage I, Stage II and Stage III disease, the prognosis of ATTR V122I cardiac
amyloidosis was slightly poorer in all three stages. In looking for a possible explanation of
this, we noted that eGFR values within each disease stage were similar between patients with
V122I and wild-type ATTR amyloidosis, but median NT-proBNP concentration was higher
in Stage II and Stage III patients with V122I (median 5176 ng/L and 9527 ng/L respectively)
compared to wild-type cases (4212 ng/L and 7776 ng/L respectively). This suggests that the
V122I patients may have had slightly more advanced disease at baseline, which is supported
further by a higher proportion of this group having NYHA class III/IV heart failure at
baseline (Table 1). However, poorer survival of patients with V122I-associated ATTR
amyloidosis might also reflect a more aggressive disease phenotype or poorer efficacy of
supportive heart failure treatment in black individuals. Further studies to determine which of
these factors is responsible for the prognostic differences highlighted here will be greatly
enhanced by use of this staging system.
Although there is a correlation between NT-proBNP concentration and eGFR in the
general population, the NT-proBNP concentrations that were observed in this patient group
and, more importantly, the cutoff of 3000 ng/L is higher than that expected in patients with
end-stage renal disease who are euvolaemic and free of significant cardiac disease. The
relationship between these two biomarkers in patients with cardiac ATTR amyloidosis, a
cause of type 2 cardio-renal syndrome, is complex and reflects a combination of factors
including degree of cardiac infiltration, fluid status, hormonal axes, diuretic requirements and
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renal perfusion potentially influenced by renovascular amyloid, thus justifying their
combined use within the same model.
Until recently there was no therapy known to alter the natural history of cardiac
ATTR amyloidosis. However, several promising treatments have lately emerged for
neuropathic ATTR amyloidosis, including antisense oligonucleotide and siRNA therapies,
which inhibit TTR production by 80-90% and appear to substantially diminish disease
progression.14,23 These therapies are currently in phase 3 clinical trials in patients with
hereditary, predominantly neuropathic ATTR amyloidosis and will require evaluation in
cardiac ATTR amyloidosis. Although a study of revusiran, the first of these agents to be
tested in cardiac ATTR amyloidosis, was discontinued prematurely due to a mortality
imbalance, further studies of TTR-lowering therapy in cardiac ATTR amyloidosis are likely
to follow. Similarly, diflunisal and tafamidis, small molecule drugs that stabilise the
circulating TTR tetramer, have shown clinical benefit in neuropathic ATTR amyloidosis24,25
and tafamidis is currently undergoing evaluation in a phase 3 study in patients with cardiac
ATTR amyloidosis. Lastly, a novel antibody therapy, which has been shown to clear hepatic
and renal amyloid deposits,16 is shortly to be evaluated in patients with cardiac ATTR
amyloidosis. The existence of a validated staging system for ATTR amyloid
cardiomyopathy, applicable to patients with both wild-type and variant ATTR amyloidosis,
analogous to the ‘Mayo’ disease staging system that has very successfully been employed to
stratify patients with systemic AL amyloidosis,26 will undoubtedly facilitate the clinical
development of these promising novel therapies.
In summary, we present here a simple, novel staging system for cardiac ATTR
amyloidosis, based on two universally measured biomarkers, which stratifies patients with
both wild-type and variant ATTR amyloid cardiomyopathy into prognostic categories. This
14
staging system represents an important advance in the management of cardiac ATTR
amyloidosis.
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Figure Legends
Figure 1. Kaplan Meier curves showing survival probabilities in patients with cardiac ATTR
amyloidosis.  A) Stratified by eGFR ≥ 45 ml/min/1.73m2 vs < 45 ml/min/1.73m2 (Log rank
test, p<0.0001).  B) Stratified by NT-proBNP ≤ 3000 ng/L vs > 3000 ng/L (Log rank test, 
p<0.0001).
Figure 2. Kaplan Meier curves showing survival probabilities in 869 patients with cardiac
ATTR amyloidosis stratified by disease stage (Log rank test; Stage I vs Stage II, p<0.0001;
Stage II vs Stage III, p<0.0001).
Figure 3. Kaplan Meier curves showing survival probabilities in 553 patients with wild-type
ATTR cardiac amyloidosis stratified by disease stage (Log rank test; Stage I vs Stage II,
p<0.0001; Stage II vs Stage III, p=0.0003).
Figure 4. Kaplan Meier curves showing survival probabilities in 201 patients with V122I-
associated cardiac ATTR amyloidosis stratified by disease stage (Log rank test; Stage I vs
Stage II, p=0.006; Stage II vs Stage III, p=0.013).
Figure 5. Kaplan Meier curves showing survival probabilities in 115 patients with non-
V122I-associated variant ATTR cardiac amyloidosis stratified by disease stage. In order to
satisfy the proportional hazards assumption, separate analyses were performed before and
after 18 months, the time at which the curves cross (Before 18 months: Log rank test; Stage I
vs Stage II, p=0.72; Stage II vs Stage III, p<0.001. From 18 months: Log rank test; Stage I
vs Stage II, p=0.02; Stage II vs Stage III, p=0.25).
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Figure 6. Kaplan Meier curves showing survival probabilities in 318 with cardiac ATTR
amyloidosis (validation cohort) stratified by disease stage (Log rank test; Stage I vs Stage II,
p<0.0001; Stage II vs Stage III, p=0.01).
Table 1. Characteristics of 869 patients in test cohort and 318 patients in validation cohort
ATTR amyloidosis
(Whole test cohort)
N=869
Wild-type ATTR
amyloidosis
(Sub-group 1)
N=553
V122I-associated ATTR
amyloidosis
(Sub-group 2)
N=201
Non-V122I-associated
variant ATTR
amyloidosis
(Sub-group 3)
N=115
ATTR amyloidosis
(Validation cohort)
N=318
Median (Range) Age at diagnosis (years) 77 (41-95) 78 (51-95) 77 (47 - 90) 66 (41 - 82) 77 (30-96)
Male Sex (%) 737 (85%) 522 (94%) 143 (71%) 70 (61%) 258 (81%)
Median (Range) Creatinine (µmol/L) 108 (34 – 441) 110 (53 – 357) 119 (46 - 441) 78 (34 – 186) 102 (11-344)
Median eGFR (ml/min)
CKD stage I (n)
CKD stage II (n)
CKD stage III (n)
CKD stage IV (n)
CKD stage V (n)
61 (12 - >90)
99
358
370
39
3
58 (15 - >90)
37
221
265
30
0
62 (12 - >90)
16
89
86
7
3
83 (23 - >90)
46
48
19
2
0
65 (12 - >90)
59
121
129
8
1
Median NT-proBNP (ng/L)
  NT-proBNP ≤2000 (n) 
NT-proBNP 2001-3000 (n)
NT-proBNP 3001-4000 (n)
NT-proBNP >4000 (n)
3036 (34 – 45642)
288
145
108
328
3087 (51 – 34910)
170
96
81
206
3332 (34 – 45642)
63
33
20
85
2106 (34 – 30479)
55
16
7
37
2784 (22-40492)
126
40
41
111
Median (Range) Troponin T (ng/L) 60 (3 – 843) 60 (4 – 340) 82 (10 – 843) 38 (3 – 161) 60 (3-372)*
NYHA Class (n (%)) II
III
IV
Missing data
656 (75)
205 (24)
8 (1)
0
440 (80)
110 (20)
3 (<1
0)
119 (59)
79 (39)
3 (1)
0
97 (84)
16 (14)
2 (2)
0
147 (46)
100 (31)
23 (7)
48 (15)
Median (Range) Systolic Blood Pressure
(mmHg)
121 (72-198) 122 (72 - 184) 120 (83 - 198) 117 (91 - 158) Data unavailable
Median (Range) IVSd (mm) 17 (10-25) 17 (11 – 25) 17 (11 – 24) 16 (10 – 23) 18 (11-29)¥
Median (Range) Age at death/censor (years) 79 (42 - 96) 81 (52 – 96) 79 (48 – 92) 69 (42 - 87) 78 (30-97)
Heart Rhythm Sinus Rhythm (n)
AF (n)
Pacemaker (n)
Missing data (n)
481
303
39
46
262
235
24
32
137
44
9
11
82
24
6
3
206
53
43
16
Ischaemic Heart Disease Yes (n)
No (n)
Missing data (n)
138
685
46
116
405
32
15
175
11
7
105
3
21
282
15
* = high sensitivity troponin T only; AF = atrial fibrillation; ¥ = data missing in 64 patients
Table 2. Staging of cardiac ATTR amyloidosis. Cox proportional hazards regression
analysis, adjusting for age and including comparison of staging systems
Group Model
item
Results eGFR and NT-proBNP
Test Cohort
eGFR and NT-proBNP
Validation Cohort
TnT and NT-proBNP
Test Cohort
All cardiac ATTR
amyloidosis
Stages
II v I
HR (95%CI)
P -value
2.05 (1.54 –2.72)
<0.001
3.35 (1.79-6.29)
<0.001
2.11 (1.45-3.04)
<0.001
Stages
III v I
HR (95%CI)
P -value
3.80 (2.73-5.28)
<0.001
6.91 (3.45-13.87)
<0.001
3.33 (2.35-4.71)
<0.001
Stages
III v II
HR (95%CI)
P -value
1.86 (1.39-2.48)
<0.001
2.05 (1.12-3.79)
0.020
1.58 (1.20-2.08)
0.001
Age HR (95%CI)
P -value
1.02 (1.01-1.04)
0.004
1.02 (0.99-1.05)
0.132
1.02 (1.01-1.05)
0.002
Harrell’s c 0.69 0.71 0.69
Wild type ATTR
cardiac
amyloidosis
(Sub-group 1)
Stages
II vs I
HR (95%CI)
P -value
2.26 (1.51-3.36)
<0.001
2.51 (1.09-5.73)
0.030
1.83 (1.11-3.00)
0.017
Stages
III v I
HR (95%CI)
P -value
4.37 (2.80-6.83)
<0.001
12.03 (4.47-32.41)
<0.001
3.29 (2.11-5.12)
<0.001
Stages
III v II
HR (95%CI)
P -value
1.94 (1.34-2.81)
<0.001
4.79 (2.08-11.02)
<0.001
1.80 (1.22-2.64)
0.003
Age HR (95%CI)
P -value
1.02 (0.99-1.04)
0.16
0.99 (0.94-1.05)
0.794
1.03
0.039
Harrell’s c 0.70 0.67 0.69
V122I-associated
cardiac ATTR
amyloidosis
(Sub-group 2)
Stages
II v I
HR (95%CI)
P -value
1.91 (1.17-3.12)
0.009
7.28 (1.69-32.59)
0.009
1.48 (0.70-3.15)
0.304
Stages
III v I
HR (95%CI)
P -value
3.48 (1.94-6.27)
<0.001
1.87 (0.44-7.98)
0.009
2.75 (1.33-5.65)
0.006
Stages
III v II
HR (95%CI)
P -value
1.82 (1.06-3.13)
0.030
0.26 (0.05-1.42)
0.120
1.85 (1.16-2.96)
0.010
Age HR (95%CI)
P -value
1.02 (0.99-1.06)
0.194
1.08 (0.98-1.17)
0.108
1.02 (0.99-1.06)
0.145
Harrell’s c 0.69 0.80 0.68
Non-V122I-
associated variant
cardiac ATTR
amyloidosis
(Sub-group 3)*
Stages
II v I
HR (95%CI)
P -value
2.28 (1.04-4.98)
0.039
5.60 (1.54-20.31)
0.009
3.43 (1.46-8.07)
0.005
Stages
III v I
HR (95%CI)
P -value
4.05 (1.54-10.64)
0.005
12.28 (2.47-60.90)
0.002
3.11 (1.12-8.58)
0.029
Stages
III v II
HR (95%CI)
P -value
1.78 (0.67-4.71)
0.247
2.19 (0.96-1.05)
0.305
0.91 (0.38-2.18)
0.826
Age HR (95%CI)
P -value
1.11 (1.01-1.04)
<0.001
1.01 (0.96-1.05)
0.768
1.13 1.06-1.21)
<0.001
Harrell’s c 0.72 0.76 0.74
eGFR – estimated MDRD GFR, NT-proBNP – N-terminal pro-B-type natriuretic peptide,
TnT – Troponin T
*Since the curves in figure 5 for sub-group 3 cross at 18 months, analyses for FU of < and
≥18 months were also performed separately in order to satisfy the proportional hazards 
assumption. Before 18 months: II v I HR 1.45 (95% CI: 0.20-10.75), III v I HR 14.70 (1.46-
148.32), III v II HR 10.11 (0.91-1.12). Harrell’s c 0.62; After 18 months: II v I HR 2.55
(1.07-6.07), III v I HR 3.24 (0.98-10.65), III v II HR 1.27 (0.38-4.23). Harrell’s c 0.73
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